Stifel raised the firm’s price target on RxSight to $54 from $45 and keeps a Buy rating on the shares. After having hosted a physician call with early adopters of RxSight’s new LAL+, the firm came away net-positive on the lens’ potential to drive incremental procedure volume, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXST:
- RxSight price target raised to $41 from $35 at Needham
- RxSight up 9% in pre-market after above-consensus pre-announcement for Q4
- RxSight price target raised to $45 from $40 at Stifel
- RxSight price target raised to $45 from $42 at Wells Fargo
- RxSight sees FY24 revenue of $128M-$135M, consensus $121.48M
